WDAF-TV

Diadem Receives $2.5 Million NIH SBIR Grant to Further Validate Prognostic Utility of its Blood Test for Early Identification of Patients Who Will Progress to Alzheimer's Disease

—New Funds Intended to Support Analysis of ADNI Databases to Validate and Extend Existing Data Showing AlzoSure ® Predict Accurately Identifies Those Individuals Who Will Progress to Alzheimer's ...
KXAN

Diadem Announces First Closing of €10 Million Equity Financing for Its AlzoSure® Predict Prognostic Blood Test for Alzheimer's Disease

—CDP Venture Capital and Panakès Partners Leading Equity Financing in Association with Recent €7.5M European Investment Bank Venture Debt Commitment; Additional Venture Funds Expected to Join Equity ...
KTLA

Diadem Announces Publication of Clinical Study Confirming Its AlzoSure® Predict Blood Test Can Accurately Predict Progression to Alzheimer's Disease Six Years Before Diagnosis

MILAN, May 16, 2022 /PRNewswire/ -- Diadem SpA today announced publication of the results of a clinical validation study of its AlzoSure ® Predict prognostic blood test for Alzheimer's disease (AD).